Principal Investigator - A retrospective study of the characteristics and outcomes of patients with familial chylomicronaemia syndrome treated with volanesorsen in the United Kingdom early access to medicines scheme

Activity: Other activity typesOther

Description

Study sponsor: Akcea Therapeutics UK
Period01 Mar 20212022
Held atBelfast Health and Social Care Trust, United Kingdom
Degree of RecognitionInternational